HCPConnect

For HCPsIntended for HCPs.

Specialty News

Dermatology Intelligence.

Specialty-focused research, clinical updates, drug approvals, and peer-reviewed news for healthcare professionals.

Clinical Feed

Search medical news updates.

3 loaded
DermatologyFDA

FDA Approves Bimekizumab for Moderate to Severe Plaque Psoriasis: BE VIVID Trial Results

FDA approves bimekizumab for moderate to severe plaque psoriasis: 75% PASI reduction in BE VIVID trial.

5h ago|3 min read|Dr. Divya Agarwal
DermatologyFDA

FDA Approves Bimekizumab for Moderate to Severe Plaque Psoriasis: 75% Skin Clearance in BE VIVID Trial

Bimekizumab (Bimzelx) approved for moderate to severe plaque psoriasis: 75% skin clearance in BE VIVID trial.

Apr 29|3 min read|Dr. Rohan Gupta
DermatologyNEJM

IL-17 and IL-23 Biologics for Plaque Psoriasis: Key Comparisons for 2025

IL-17 and IL-23 biologics for plaque psoriasis: Key comparisons and emerging oral options in 2025.

Apr 29|3 min read|Dr. Divya Agarwal

End of feed